More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

A recent analysis from Clarivate Analytics’ Cortellis identifies 11 drugs that are expected to enter the market in 2020 and achieve blockbuster status by 2024. Which drugs are making the mark? Blockbuster watch: Big Pharma A recent analysis by...

Orphan drugs, defined in the US as a drug to treat less than 200,000 patients, have accounted for more than 40% of new drug approvals by the FDA over the past several years, but are they producing the revenue gains pharma companies are seeking or...

With five new molecular entities launched in 2019 and two potential blockbusters targeted for launch in 2020, is the strategy of Novartis CEO Vas Narasimhan to drive growth in the company's Innovative Medicines business, including in new modalities...

The number of parenteral drugs in the industry's pipeline and recently approved new drugs continues to rise with the increase of biologics and more complex active pharmaceutical ingredients. DCAT Value Chain Insights examines recent FDA approvals...

The FDA and FTC are collaborating to advance market competition in biologics, including for biosimilars. What have the agencies done thus far and what are they planning to do? The US market for biologics Earlier this month (February 2020), the US...

Cambrex eBook: The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021, driven by positive industry trends — many of which our experts commented on in Part 1 of the Cambrex eBook. Market data shows just how...

Small molecules still lead over biologics in recent drug approvals, accounting for nearly three-fourths of drug approvals over the past several years, but will small molecules' dominance continue? DCAT Value Chain Insights takes an inside...

The UK officially withdrew from the European Union (EU) on January 31 and now has until the end of 2020 to negotiate a trade deal with the EU. How may a trade deal unfold, and what is the impact for the pharmaceutical industry? Inside Brexit: What...

Cambrex experts have contributed more articles to our biggest eBook yet. The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities and employees than ever before. Enjoy Part 1 of our latest Cambrex...